Cullinan Therapeutics Gains on Plan for Registrational Trial of AML Drug

Shares of Cullinan Therapeutics (NASDAQ: CGEM) rose in pre-market trading after the company announced a clear regulatory path forward for its acute myeloid leukemia (AML) drug candidate, CLN-049, following constructive feedback from the U.S. Food and Drug Administration (FDA).

FDA Feedback Paves Way for Pivotal Study

Cullinan announced that following an End-of-Phase 1 meeting with the FDA, it plans to initiate a potentially registrational Phase 2 study of CLN-049 in the third quarter of 2026. The drug, a novel FLT3xCD3 bispecific T cell engager, is being developed for patients with relapsed or refractory (R/R) AML.

The company described the feedback from the agency as constructive. The planned study design includes a short dose-optimization phase followed by a single-arm expansion cohort, a streamlined structure that investors interpreted as an accelerated and de-risked path toward potential regulatory approval.

Market Reaction and Context

Ad

In response to the news, Cullinan's stock rose 2.1% in pre-open trading toward $17.80. The advance was a company-specific development, standing in contrast to a weaker Nasdaq and only modest gains in the S&P 500 and Dow Jones.

The positive update builds on previous regulatory milestones that have supported the CLN-049 program. The asset already holds both FDA Fast Track and Orphan Drug designations for R/R AML, which are intended to facilitate development and expedite the review of drugs for serious conditions.

Cullinan also disclosed plans to initiate a separate Phase 1/2 combination study. This trial will evaluate CLN-049 with venetoclax and azacitidine in previously untreated AML patients, signaling a strategy to broaden the drug's potential addressable market.